SIRT2 Contributes to the Resistance of Melanoma Cells to the Multikinase Inhibitor Dasatinib

SIRT2 Contributes to the Resistance of Melanoma Cells to the Multikinase Inhibitor Dasatinib

Malignant melanoma is the most aggressive skin cancer and can only be cured if detected early. Unfortunately, later stages of the disease do not guarantee success due to the rapid rate of melanoma cell metastasis and their high resistance to applied therapies. The search for new molecular targets an...

Full description

Bibliographic Details
Main Authors: Iwona Karwaciak, Anna Sałkowska, Kaja Karaś, Marta Sobalska-Kwapis, Aurelia Walczak-Drzewiecka, Łukasz Pułaski, Dominik Strapagiel, Jarosław Dastych, Marcin Ratajewski
Format: Article
Language:English
Published: MDPI AG 2019-05-01
Series:Cancers
Subjects:
melanoma, SIRT2, sirtuins, tyrosine kinase, resistance
Online Access:https://www.mdpi.com/2072-6694/11/5/673

Internet

https://www.mdpi.com/2072-6694/11/5/673

Similar Items